Farmas USA

Aquí el golpe de efecto seria llamar a la puerta de la EMA.
Joe!!!!! Europa para cuandoooooo??????

AMRN

Hombre....la dirección cobra autenticas burradas como para que lo hayan considerado ya hace mucho tiempo....vamos digo yo.
AMRN

Edito: Pensándolo mejor, si lo van a hacer sin un partner, mejor que no lo hagan porque palmamos pasta.

Si, si, por supuesto, aqui cualquier mvto que hagan tiene que ir de la mano de alguien.
Lo de ir en solitario se acabó o deberia acabarse.
Lo de la imperiosa necesidad de partner queda ya implícitamente incluido en toda conversación sobre el debido futuro de Amarin.

AMRN

Eso lo llevo pesando mucho tiempo, es presentarlo y aprobado, eso si necesitan el partner para venderlo
AMRN

han visto bmsn muy barato muchas atentes eb fase clinica

Enhorabuena!
Ya tienes el record de la farma mas pequeña jamas presentada en este hilo.

Por favor caballero, eso en este hilo
https://www.rankia.com/foros/bolsa/temas/1425027-chicharros-usa-bolsa-internacional?page=123#respuesta_2055451

Amarin Announces Notification of Patent Allowances for U.S. Applications 13/685,281, and 13/685,291 Related to Triglyceride Lowering With a Mixture of Omega-3 Free Fatty Acid (Including EPA and/or DHA) in Both the MARINE and ANCHOR Patient Populations

BEDMINSTER, N.J., and DUBLIN, Ireland, Dec. 2, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the United States Patent and Trademark Office (USPTO) has published notification of a Notices of Allowance for Amarin's U.S. Patent Applications Serial Numbers 13/685,281, and 13/685,291, each titled "Stable Pharmaceutical Composition and Methods of Using Same." The claims in these allowed applications cover methods of lowering triglycerides by administering a pharmaceutical composition comprised of a mixture of free fatty acids, including EPA and/or DHA to varying degrees, to patients with severe hypertriglyceridemia (the MARINE population) and in patients with hypertriglyceridemia on concomitant statin therapy (the ANCHOR population). A Notice of Allowance is issued after the USPTO makes a determination that a patent can be granted from an application. The issued patents would have terms that expire no earlier than in 2030.

These applications are part of an expanding patent portfolio for Amarin with 38 patent applications now either issued or allowed with the USPTO and over 30 additional applications pending in the United States.

AMRN

Venga...push, push...Fernando push, push....
=P